ArticleCommunications medicine2026

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.

Xiaohua Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.